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Abstract
Background: Mycobacterium tuberculosis resistance to anti-tuberculosis drugs is a major threat to global public
health. Whole genome sequencing (WGS) is rapidly gaining traction as a diagnostic tool for clinical tuberculosis
settings. To support this informatically, previous work led to the development of the widely used TBProfiler webtool,
which predicts resistance to 14 drugs from WGS data. However, for accurate and rapid high throughput of samples
in clinical or epidemiological settings, there is a need for a stand-alone tool and the ability to analyse data across
multiple WGS platforms, including Oxford Nanopore MinION.
Results: We present a new command line version of the TBProfiler webserver, which includes hetero-resistance
calling and will facilitate the batch processing of samples. The TBProfiler database has been expanded to incorporate
178 new markers across 16 anti-tuberculosis drugs. The predictive performance of the mutation library has been
assessed using > 17,000 clinical isolates with WGS and laboratory-based drug susceptibility testing (DST) data. An
integrated MinION analysis pipeline was assessed by performing WGS on 34 replicates across 3 multi-drug resistant
isolates with known resistance mutations. TBProfiler accuracy varied by individual drug. Assuming DST as the gold
standard, sensitivities for detecting multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) were
94% (95%CI 93–95%) and 83% (95%CI 79–87%) with specificities of 98% (95%CI 98–99%) and 96% (95%CI 95–
97%) respectively. Using MinION data, only one resistance mutation was missed by TBProfiler, involving an
insertion in the tlyA gene coding for capreomycin resistance. When compared to alternative platforms (e.g.
Mykrobe predictor TB, the CRyPTIC library), TBProfiler demonstrated superior predictive performance across first-
and second-line drugs.
Conclusions: The new version of TBProfiler can rapidly and accurately predict anti-TB drug resistance profiles
across large numbers of samples with WGS data. The computing architecture allows for the ability to modify
the core bioinformatic pipelines and outputs, including the analysis of WGS data sourced from portable technologies.
TBProfiler has the potential to be integrated into the point of care and WGS diagnostic environments, including in
resource-poor settings.
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Background
Tuberculosis disease (TB), caused by Mycobacterium tu-
berculosis, is the world’s major cause of death from an in-
fectious agent [1]. The emergence of multi-drug-resistant
tuberculosis (MDR-TB) is leading to difficulties in disease
control. MDR-TB is resistance to at least rifampicin and
isoniazid, and extensive drug resistance (XDR-TB) is the
additional resistance to the fluoroquinolones and inject-
able drugs (amikacin, kanamycin and capreomycin) used
to treat MDR-TB. Phenotypic methods of determining
susceptibility to anti-tuberculosis drugs (DSTs) can take
weeks and require culturing of M. tuberculosis. Drug re-
sistance in M. tuberculosis is almost exclusively due to
mutations (including single nucleotide polymorphisms
(SNPs), insertions and deletions (indels)) in genes coding
for drug targets or converting enzymes. Putative compen-
satory mechanisms have been described to overcome fit-
ness impairment that arises during the accumulation of
resistance-conferring mutations [2].
Molecular characterisation of resistance from the M.
tuberculosis circular genome (size 4.4 Mb) offers a rapid
alternative to traditional culture-based methods. Com-
mercial PCR-based tests and line probe assays are avail-
able for a limited number of drugs but, with the
exception of rifampicin, they have low sensitivity for de-
tecting all possible molecular targets for resistance [3].
Due to the multiplicity of drugs used in the treatment of
TB, determining the full resistance profile for a patient
suspected of having drug-resistant disease requires the
analysis of many genetic loci. Further, new mutations are
being uncovered using genome-wide association and
convergent evolution studies and revealing an important
role for indels and copy number variants in drug resist-
ance [4]. Whole genome sequencing (WGS) offers an at-
tractive option as it simultaneously examines all loci and
provides information regarding both small and large
changes in the genome [3], allowing for the prediction of
resistance and potentially susceptibility [5]. Third-
generation portable sequencing technologies, such as
Oxford Nanopore MinION [6], offer opportunities to
roll out WGS as a diagnostic in the less well-resourced
settings found in countries where TB is endemic. How-
ever, this requires efficient and automated informatic
platforms to enable the data to be analysed without ne-
cessarily needing a trained genomics expert. For accept-
ance as a diagnostic tool to guide treatment of drug-
resistant TB, the sequencing platforms and analytical
tools employed must be robust and reliable.
Previously we released the TBProfiler webserver that
allowed researchers to upload raw sequence data to re-
trieve a report with information on lineage and resist-
ance across 14 anti-TB drugs. To date, this tool has been
used to profile tens of thousands of isolates to produce
high-quality reports and has been shown to outperform
other software [7] and established diagnostic tools [3].
The underlying mutation library consists of 1193 poly-
morphisms across 32 targets conferring resistance to the
14 anti-tuberculous drugs. As our understanding of the
molecular mechanisms of resistance is improving, such
libraries of mutations need to be regularly updated. Fur-
ther, there is a need to characterise genomic hetero-
resistance in candidate loci, where both sensitive and re-
sistance alleles of the same mutation are present in a
sample. It has been shown that identifying hetero-
resistance can lead to better predictions of the drug re-
sistance phenotypes (e.g. XDR-TB [8]). More generally,
whilst the web interface greatly simplifies the process of
analysing raw sequence data, it may not be convenient
for all settings. For example, a stand-alone tool may be
useful in areas where internet access is slow or not avail-
able, or parallel profiling of hundreds of strains is
required.
In this study, we update the TBProfiler library to in-
clude mutations for two further drugs used in the treat-
ment of drug-resistant TB, cycloserine and delamanid.
To improve the tool’s utility, a command line implemen-
tation has been developed, with hetero-resistance char-
acterisation, and the capacity for processing of large-
scale data, potentially from multiple WGS platforms
(e.g. Illumina, MinION). The performance of the TBPro-
filer pipeline is compared to DST outcomes across >
17kM. tuberculosis strains from over 50 countries with
Illumina WGS data, as well as on a subset that has
undergone cutting edge MinION WGS.
Implementation
Resistance mutation library
New mutations were added to an existing robust TBProfi-
ler library [3], with inclusion based on evidence from re-
cent publications [4, 9, 10]. In total, 178 new mutations
were added to the library across 16 drugs, including for
cycloserine and delamanid, not present in the previous
version of the library. This library is hosted on GitHub
(https://github.com/jodyphelan/tbdb), and details on vari-
ants included can also be found in supplementary mate-
rials (Additional file 1: Data S1). GitHub hosting allows
for changes in the mutation library to be discussed,
tracked and visualised. Different versions of the library
can be maintained using Forks, allowing users to experi-
ment with the library without affecting the main project.
These changes can then be merged into the main reposi-
tory after the changes are reviewed. Multiple users/devel-
opers can contribute towards the library.
In silico profiling of M. tuberculosis resistance phenotypes
A new TBProfiler tool for in silico prediction of drug re-
sistance and strain lineage linked to the mutation library
was developed using the Python computing language
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and well-established bioinformatic tools such as trimmo-
matic, BWA/bowtie2 and SAMtools. The new pipeline
can be customised (Additional file 2: Figure S1), but in
its default mode, reads are trimmed using trimmomatic
(parameters: LEADING:3 TRAILING:3 SLIDINGWIN-
DOW:4:20 MINLEN:36) then mapped to the H37Rv ref-
erence (AL123456) using bowtie2 (parameters: default).
Variants are called using BCFtools mpileup (parameters:
-ABq0 -Q0 -a DP, AD) and BCFtools call (parameters:
-mg 10) and annotated using BCFtools csq (parameters:
-p m) and is parallelised with GNU parallel [11]. Vari-
ants are annotated with BCFtools csq, which handles
multiple variants in the same codon jointly. Annotated
variants are compared to the TBProfiler library database.
The TBProfiler pipeline calculates the proportion of the
reads supporting each allele and reports this informa-
tion, which can serve as a proxy for phenotypic hetero-
resistance. Deletion calling is performed using Delly soft-
ware [12]. The TBProfiler pipeline is available on GitHub
(from https://github.com/jodyphelan/TBProfiler) and is
easily installed through the bioconda channel [13]. A full
set of new features can be found in supplementary
materials (see Additional file 2: Table S1). TBProfiler re-
port outputs are written in json, txt and pdf formats,
with options to collate data into multi-sample reports
(Additional file 2: Figure S3). The collated data can be
graphically viewed on top of a phylogenetic tree using
iTOL. Config files can be generated and uploaded to
iTOL to visualise drug resistance types, lineage and indi-
vidual drug resistance predictions.
Sequencing data
A database of 17,239 strains for which DST and Illumina
WGS raw data is published and publicly available was
collated (see Additional file 2: Table S2-S4; Figure S2). In
addition, M. tuberculosis isolates from three patients
(por5–7; 11–12 replicates each) with known drug-
resistant M. tuberculosis were cultured and DNA was
extracted for Oxford Nanopore MinION sequencing. Se-
quencing libraries of the isolates were prepared from
DNA extracts using the SQK-LWB001 Kit (Oxford
Nanopore Technologies, Oxford). Briefly, 100 ng of
DNA from each isolate was sheared at 6000 rpm in a g-
tube (Covaris, Woburn, MA). The fragmented DNA was
end-repaired and dA-tailed using NEBNext® Ultra™ II
End Repair/dA-Tailing Module (New England BioLabs,
Ipswich, MA) following the manufacturer’s protocol.
End-prepped DNA was purified using AM-Pure XP
beads (Beckman Coulter, Brea, CA) at 0.4× concentra-
tion, washed twice with 70% ethanol and eluted in
nuclease-free water. Purified end-prepped DNA was in-
cubated with Barcode Adaptor (BCA) from the SQK-
LWB001 kit and NEB Blunt/TA Ligase Master Mix
(New England BioLabs, Ipswich, MA) for 20 min at
room temperature. The BCA-ligated DNA was once
again purified using AMPure XP beads at 0.4× concen-
tration, washed twice with 70% ethanol and eluted in
nuclease-free water. Ten nanogrammes of DNA from
each prep was amplified using a unique set of barcode
primers provided with the SQK-LWB001 kit. The PCR
conditions are summarised in the supplementary mate-
rials (see Additional file 2: Table S5). The PCR products
were separately purified using AMPure XP beads at 0.4×
concentration, washed twice with 70% ethanol and
eluted in 10 μl of 10 mM Tris-HCl pH 8.0 with 50mM
NaCl. The barcoded libraries were pooled together to a
total of 200 fmol in an equimolar ratio in 10 μl of 10
mM Tris-HCl pH 8.0 with 50mM NaCl. The pooled li-
brary was incubated with 1 μl of RPD adapter (provided
in the SQK-LWB001 kit) and incubated for 5 min at
room temperature. The libraries were then loaded onto
FLO-MIN106 (R9.4) flow cells following standard ONT
protocols. Base calling was performed using Oxford
Nanopore’s Albacore software using default parameters.
The strains have previously been characterised both
phenotypically using DST and genotypically using Illu-
mina MiSeq and Sanger sequencing [14].
The performance of the TBProfiler tool
To test the performance of the library, the WGS raw
data for the 17,239 strains were processed through the
new TBProfiler pipeline. The predictions from the tool
were compared to the DST data (assumed to be the gold
standard) and used to calculate the sensitivity and speci-
ficity of the library. The fastQ files from the MinION se-
quencing were also processed by TBProfiler (using
parameters -m minION). Similarly, the predictive ability
was compared to those from an alternative tool, Myk-
robe-predictor TB tool [8], which was implemented using
its command-line version (v0.5.6-0-gbd7923a-dirty; pa-
rameters: --expected_error_rate 0.15). The predictive
ability for the CRyPTIC library [5] was calculated by
transforming the published mutation list to a compatible
library for TBProfiler, which was then run with default
parameters.
Results
The existing TBProfiler mutation library was updated to
include 178 new mutations, 4 new targets and 2 new
drugs. The overall number of unique mutations in the li-
brary is 1296 (see Table 1 for a summary). The TBProfi-
ler pipeline was run across the ~ 17 k strains for which
DST and high quality WGS data was available. These
strains represent all lineages, with the majority in line-
ages 1 (10.9%), 2 (21.6%), 3 (16.7%) and 4 (49.5%), and
the remaining isolates belonging to lineages 5, 6, 7 and
Mycobacterium bovis (1.2%). The majority of strains
(64.2%) were pan-susceptible, while 22.3% were MDR-
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TB and 2.0% were XDR-TB, and the remaining 11.5%
were non -MDR-TB or -XDR-TB with resistance to at
least one drug (termed “drug resistant”) (Additional file 2:
Table S2). Drug susceptibility phenotypes for 16 drugs
were collated and vary in their degree of completeness
across the dataset. The most complete DSTs were avail-
able for the first line treatments such as rifampicin (N =
17,040; 98.8%) and isoniazid (N = 16,955; 98.4%), with
the lowest for the second-line treatments (e.g. cycloser-
ine, N = 402, 2.3%) (Additional file 2: Table S3).
Genotypic hetero-resistance was present in 28 of the
32 drug targets (Additional file 2: Table S6), including
Rv0678, which reflects the observed complex nature of
resistance acquisition [15]. The predictive ability of
TBProfiler across all 16 drugs was calculated by compar-
ing the inferred resistance calls against the reported
DST result (Table 2). The sensitivity ranged from 95.9%
(rifampicin) to 23.8% (para-aminosalicylic acid (PAS)).
The sensitivities for first-line treatments such as rifampi-
cin, isoniazid and ethambutol were high (> 90%), but
lower for pyrazinamide (87.6%). The low sensitivity for
pyrazinamide could potentially be attributed to the high
number of rare variants in the pncA gene, where almost
half (292/624) of variants were unique to single isolates.
These rare variants may influence resistance levels. Add-
itionally, to calculate the performance of our approach,
we assumed phenotypic DST to be the gold standard.
However, incorrect DST data could explain some false
results. For example, M. bovis is intrinsically resistant to
pyrazinamide, but 30% of isolates obtained from the
public domain for this study were classed as sensitive to
pyrazinamide. Ethionamide sensitivity was estimated at
89.5%, while the specificity was 67.4%. The high number
of false positives for ethionamide may be influenced by
the level of resistance conferred by inhA promoter mu-
tations. These levels may be close to, but under the crit-
ical concentration, and the subsequent DST result will
not reflect this.
Sensitivity to the second-line injectables ranged between
84.7% for capreomycin and 92.0% for kanamycin. The sen-
sitivity for fluoroquinolones was high and ranged from
86.0% for moxifloxacin to 90.6% for ciprofloxacin. The
variants conferring resistance to the individual drugs in
the fluoroquinolone class do not differ in our library, and
the differences in sensitivity are attributable to the vari-
ability in DST across the drugs. The overall sensitivity for
the fluoroquinolones class reported by TBProfiler was
89.1%. Sensitivities for PAS (23.8%) and cycloserine
(43.0%) were low, indicating difficulties either with un-
known molecular mechanisms or with DST. The predict-
ive value for assigning MDR-TB and XDR-TB to isolates
was high, with sensitivities at 94.1% and 83.4% respect-
ively. Additionally, 96.5% of pan-susceptible isolates with
complete phenotypic data for the first-line drugs were
Table 1 Summary of mutations included in the curated whole
genome drug resistance TBProfiler library
Drug Locus Gene SNPs (No. obs*) Indels (No. obs*)
Rifampicin Rv0667 rpoB 94 (57) 25 (8)
Rv0668 rpoC 8 (8) 0 (0)
Isoniazid Rv1483 fabG1 11 (5) 0 (0)
Rv1484 inhA 13 (6) 0 (0)
Rv1908c katG 226 (78) 37 (9)
Rv2245 kasA 4 (1) 0 (0)
Rv2428 ahpC 21 (10) 0 (0)
Ethambutol Rv1267c embR 20 (3) 0 (0)
Rv3793 embC 25 (4) 0 (0)
Rv3794 embA 9 (5) 6 (0)
Rv3795 embB 127 (52) 1 (0)
Pyrazinamide Rv1630 rpsA 3 (1) 0 (0)
Rv2043c pncA 280 (221) 87 (36)
Rv3601c panD 10 (3) 1 (0)
Streptomycin Rv0682 rpsL 16 (6) 0 (0)
Rv3919c gid 2 (1) 26 (15)
rrs rrs 19 (15) 0 (0)
Ethionamide Rv1483 fabG1 3 (3) 0 (0)
Rv1484 inhA 3 (3) 0 (0)
Rv3854c ethA 33 (23) 42 (39)
Rv3855 ethR 2 (2) 0 (0)
Amikacin rrs rrs 6 (5) 0 (0)
Capreomycin Rv1694 tlyA 16 (2) 13 (2)
rrs rrs 4 (4) 0 (0)
Kanamycin Rv2416c eis 10 (8) 0 (0)
rrs rrs 4 (4) 0 (0)
FQ Rv0005 gyrB 26 (20) 0 (0)
Rv0006 gyrA 21 (17) 0 (0)
PAS Rv2447c folC 18 (10) 0 (0)
Rv2671 ribD 1 (1) 0 (0)
Rv2754c thyX 1 (1) 0 (0)
Rv2764c thyA 19 (9) 5 (0)
Cycloserine Rv2780 ald 0 (0) 12 (10)
Rv3423c alr 3 (3) 0 (0)
Linezolid Rv0701 rplC 1 (1) 0 (0)
rrl rrl 2 (1) 0 (0)
Bedaquiline Rv0678 Rv0678 5 (0) 2 (1)
Clofazimine Rv0678 Rv0678 5 (0) 2 (1)
Delamanid Rv3261 fbiA 1 (0) 0 (0)
Drugs which are new to the library are bolded; indels insertions and deletions,
FQ fluoroquinolones, PAS para-aminosalicylic acid. *Number of mutations
observed in the ~ 17 k dataset
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correctly predicted. The specificity of the library was
greater than 90% for all comparisons apart from ethion-
amide (Table 2). The sensitivities of Mykrobe-Profiler TB
and the library published by the CRyPTIC consortium
were lower than those from TBProfiler, and specificities
broadly similar (Additional file 2: Table S7).
To assess the ability of TBProfiler to perform in silico
profiling using MinION data, 34 replicates underwent
WGS across one MDR-TB (por5) and two XDR-TB (por6
and por7) isolates (Table 3). The median read depth after
mapping was 53-fold coverage (range: 25–141) and led to
on average 96.4% of the genome being covered by at least
10 reads. Across the 34 isolates and 10 drugs, there was
high concordance between drug resistance mutations in-
ferred by TBProfiler from the analysis of MinION and al-
ternative Illumina and Sanger sequencing data (328/340,
94.5%). Identical mutations were identified across each set
of replicates, indicating the high reproducibility of the
variant calling pipeline. The discrepancies between the
MinION and Illumina data were found in por7 replicates
(n = 12), where the Illumina data revealed a frameshift in-
sertion (751T>TTG) in the tlyA gene associated with
capreomycin resistance. This insertion could not be called
using the MinION data, due to known issues regarding
Table 2 Accuracy of the TBProfiler library
Drug Total Susceptible Resistant TB Profiler sensitivity (%) TB Profiler specificity (%)
Rifampicin 17,040 12,473 4564 95.9 98.2
Isoniazid 16,955 11,599 5295 93.7 98.1
Ethambutol 15,334 12,698 2617 92.1 91.7
Pyrazinamide 12,381 10,447 1875 87.6 96.7
Streptomycin 5366 3992 1288 78.0 96.3
Ethionamide 987 649 332 89.5 67.4
Amikacin 1480 1138 342 86.0 98.3
Capreomycin 1783 1388 393 84.7 95.9
Kanamycin 1908 1252 653 92.0 96.8
Ciprofloxacin 406 342 64 90.6 98.0
Moxifloxacin 905 798 107 86.0 91.9
Ofloxacin 2060 1543 514 90.1 96.5
Fluoroquinolones 2532 1944 539 89.1 97.1
PAS 418 373 42 23.8 96.7
Cycloserine 402 295 107 43.0 92.5
MDR-TB 16,879 11,293 4151 94.1 98.3
XDR-TB 2026 1681 343 83.4 96.4
MDR-TB multi-drug-resistant TB, XDR-TB extensively drug-resistant TB, PAS para-aminosalicylic acid, − could not be determined
Table 3 The in-silico profiling results for isolates sequenced using MinION
Samples* Method RIF INH EMB PYR STR ETH AMK CAP FLQ PAS
por5 DST R R R R R R S S S S
TBProfiler R R R R R R S S S S
Mykrobe** R R R 82%R R – S S S –
por6 DST R R R R R R R R R S
TBProfiler R R R R R R R R R S
Mykrobe R R R R R – 82%R 82%R R –
por7 DST R R R R R R R R R S
TBProfiler R R R R R R S S R S
Mykrobe R 92%R S R 83%R – S S 91%R –
DST drug susceptibility testing (R resistant, S sensitive); this table shows the percentage of replicates producing the correct result; − cannot be determined; bolded
values indicate the % of replicates with DST phenotypes, where resistance mutations are not found in all replicates. Underlined values indicate where the variant
is not present in software mutation library; RIF rifampicin, INH isoniazid, EMB ethambutol, PYR pyrazinamide, STR streptomycin, ETH ethionamide, AMK amikacin,
CAP capreomycin, FLQ fluoroquinolones, PAS para-aminosalicylic acid. *All LAM4 strain-types or sub-lineage 4.3.4.2. **Mykrobe-Profiler TB (https://github.com/iqbal-
lab/Mykrobe-predictor) implemented using its command-line version
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indel characterisation. Allele counts from the reads map-
ping to position 751 in the tlyA gene revealed that the re-
sistance mutation was in a minority. Mykrobe-predictor
TB was also assessed for its ability to correctly call variants
in drug resistance candidates. Greater discrepancies were
observed using this pipeline, with discordant results across
six drugs (Table 3).
Discussion
Advances in WGS technology have expanded a role for
genome analysis in the clinical laboratory. Determining
resistance to anti-tuberculosis drugs by WGS has been
demonstrated as feasible and is being implemented in
some specialist centres [5] where it has been found to be
a cost effective option [16]. We have previously shown
the robustness of variant calling tools to detect SNPs,
small indels and large deletions from WGS data [14]. As
WGS is adopted more widely as a diagnostic tool, there
is a need for robust and reliable software tools to process
the vast amounts of data generated. Additionally, the
growing application of third generation sequencing plat-
forms, such as the Oxford Nanopore MinION, has
driven the need to integrate analysis options for these
technologies into profiling tools to support their use in a
more automated format than available currently. To aid
the implementation of WGS for detecting resistance to
anti-tuberculosis drugs in current clinical use, the
TBProfiler tool has been completely rewritten to enable
the rapid processing of raw sequence data using a com-
mand line interface. Flexible and editable multi-sample
reports with outputs to annotate phylogenetic trees can
assist with epidemiological and clinical interpretation.
Additionally, evidence of hetero-resistance is now re-
ported based on the frequency of resistant alleles in the
sequence reads. However, the absence of evidence in the
sequences does not rule out phenotypic hetero-
resistance due to culture methods applied for obtaining
DNA for sequencing. Together with the new pipeline,
we provided an updated library and report a high sensi-
tivity and specificity for MDR-TB and XDR-TB. Add-
itionally, the tool allows for the flexible use of different
libraries such as those provided by ReSeqTB [17].
TBProfiler includes options to analyse data from the
MinION platform, which can have a high error rate, and
therefore requires different tools and parameters. The
MinION technology promises expanded access to WGS,
due to its portability and ability to sequence directly
from sputum samples [18]. As rapid sequencing from
metagenomic samples to detect M. tuberculosis and pro-
file resistance becomes a reality, tools to process this
data are required. We demonstrated the successful appli-
cation of the TBProfiler MinION pipeline across 34 rep-
licates covering 3 drug-resistant isolates, which have
been also undergone Illumina and Sanger sequencing. In
particular, we found a high concordance between repli-
cates and across technologies, with the only difference be-
ing an insertion in the tlyA gene, which suggests that it is
important to go beyond SNPs for resistance prediction.
More generally, as our knowledge of resistance mecha-
nisms grows, prediction software must allow for the flexi-
bility and customisation of resistance databases. There is a
constant need to update, re-evaluate and improve muta-
tion libraries in response to new evidence. However, a
number of published mutation libraries are no longer
maintained and remain static versions of evidence at the
time. To circumvent this limitation, we have hosted the li-
brary on a repository that facilitates user input.
In summary, WGS has the potential to improve the
resolution and timeliness of TB diagnosis, and in combin-
ation with robust DST, can lead to new insights into drug
resistance mechanisms. The upgraded TBProfiler tool al-
lows for the flexible and rapid analysis of WGS data from
Illumina and MinION platforms to predict drug resistance
and strain type profiles with high accuracy.
Conclusions
We have shown that online and stand-alone versions of
TBProfiler can be used to reliably profile M. tuberculosis
drug resistance from WGS. This pipeline can be applied
to data from multiple sequencing platforms and can sup-
port informatically the application of WGS as a diagnos-
tic for TB clinical management, either in combination
with culture or ultimately directly from patient samples.
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